Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI – Get Free Report) dropped 7.2% during trading on Friday . The stock traded as low as $0.18 and last traded at $0.18. Approximately 383,038 shares were traded during mid-day trading, a decline of 89% from the average daily volume of 3,360,357 shares. The stock had previously closed at $0.20.
Analysts Set New Price Targets
Several research analysts have weighed in on CLDI shares. HC Wainwright lowered their target price on shares of Calidi Biotherapeutics from $11.00 to $2.00 and set a “buy” rating on the stock in a research report on Thursday, March 21st. Robert W. Baird lowered their price target on Calidi Biotherapeutics from $4.50 to $2.00 and set an “outperform” rating on the stock in a report on Wednesday, May 15th.
Get Our Latest Research Report on CLDI
Calidi Biotherapeutics Price Performance
Hedge Funds Weigh In On Calidi Biotherapeutics
Several hedge funds have recently bought and sold shares of the stock. Magnetar Financial LLC purchased a new stake in shares of Calidi Biotherapeutics in the first quarter valued at $36,000. Evermay Wealth Management LLC purchased a new stake in Calidi Biotherapeutics during the 1st quarter worth about $36,000. Apollo Management Holdings L.P. acquired a new position in Calidi Biotherapeutics in the 1st quarter valued at about $71,000. Finally, Spectrum Asset Management Inc. NB CA purchased a new position in Calidi Biotherapeutics in the 1st quarter valued at about $94,000. Hedge funds and other institutional investors own 12.53% of the company’s stock.
About Calidi Biotherapeutics
Calidi Biotherapeutics, Inc, a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors.
Recommended Stories
- Five stocks we like better than Calidi Biotherapeutics
- Canadian Penny Stocks: Can They Make You Rich?
- Sarepta Therapeutics Stock Soars on FDA Approval
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- CarMax: A Market Melt-Up Waiting to Happen for this Stock
- 3 Warren Buffett Stocks to Buy Now
- 3 Solar Stocks to Watch that are Building the Green Energy Future
Receive News & Ratings for Calidi Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calidi Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.